Dr. Hermann Reichegger
Oberarzt mbF
Medizinische Onkologie und Hämatologie · Dept. I
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Dieckmann K, Heinzelbecker J, Heidenreich A, Cremers J, Oing C, Hermanns T, Fankhauser C, Gillessen Sommer S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Ruf C, Loidl W, Haben B, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Belge G. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol 2019; 37:1412-1423.
15.03.2019Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
15.03.2019J Clin Oncol 2019; 37:1412-1423
Dieckmann Klaus-Peter, Heinzelbecker Julia, Heidenreich Axel, Cremers Jann Frederik, Oing Christoph, Hermanns Thomas, Fankhauser Christian Daniel, Gillessen Sommer Silke, Reichegger Hermann, Cathomas Richard, Pichler Martin, Hentrich Marcus, Eredics Klaus, Lorch Anja, Wülfing Christian, Peine Sven, Wosniok Werner, Bokemeyer Carsten, Ruf Christian Guido, Loidl Wolfgang, Haben Björn, Radtke Arlo, Geczi Lajos, Matthies Cord, Anheuser Petra, Eckardt Ulrike, Sommer Jörg, Zengerling Friedemann, Trenti Emanuela, Pichler Renate, Belz Hanjo, Zastrow Stefan, Winter Alexander, Melchior Sebastian, Hammel Johannes, Kranz Jennifer, Bolten Marius, Krege Susanne, Belge Gazanfer
Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I
Fehr M, Maranta A, Reichegger H, Gillessen Sommer S, Cathomas R. Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I. ESMO Open 2018; 3:e000320.
08.03.2018Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I
08.03.2018ESMO Open 2018; 3:e000320
Fehr Martin, Maranta Angela Fischer, Reichegger Hermann, Gillessen Sommer Silke, Cathomas Richard
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Schmid S, Diebold J, Jochum W, Reichegger H, Klingbiel D, Froesch P, Mark M, Rothschild S, Gautschi O, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol 2016
19.12.2016Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
19.12.2016J Thorac Oncol 2016
Schmid Sabine, Diebold Joachim, Jochum Wolfram, Reichegger Hermann, Klingbiel Dirk, Froesch Patrizia, Mark Michael, Rothschild Sacha, Gautschi Oliver, Früh Martin
Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung
Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. Oncol Res Treat 2016; 39:461-3.
15.06.2016Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung
15.06.2016Oncol Res Treat 2016; 39:461-3
Reichegger Hermann, Jochum Wolfram, Förbs Diana, Hader Claudia, Früh Martin